Cargando…

Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease

Background: Cell-free plasma DNA (cfDNA) is circulating extracellular DNA arising from cell death mechanisms (apoptosis, necrosis, etc.). It is commonly existent in healthy individuals, but its ranks increase in diverse clinical circumstances, such as kidney disease, sepsis, myocardial infarction, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Clementi, Anna, Virzì, Grazia Maria, Manani, Sabrina Milan, de Cal, Massimo, Battaglia, Giovanni Giorgio, Ronco, Claudio, Zanella, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488719/
https://www.ncbi.nlm.nih.gov/pubmed/37685683
http://dx.doi.org/10.3390/jcm12175616
_version_ 1785103542832332800
author Clementi, Anna
Virzì, Grazia Maria
Manani, Sabrina Milan
de Cal, Massimo
Battaglia, Giovanni Giorgio
Ronco, Claudio
Zanella, Monica
author_facet Clementi, Anna
Virzì, Grazia Maria
Manani, Sabrina Milan
de Cal, Massimo
Battaglia, Giovanni Giorgio
Ronco, Claudio
Zanella, Monica
author_sort Clementi, Anna
collection PubMed
description Background: Cell-free plasma DNA (cfDNA) is circulating extracellular DNA arising from cell death mechanisms (apoptosis, necrosis, etc.). It is commonly existent in healthy individuals, but its ranks increase in diverse clinical circumstances, such as kidney disease, sepsis, myocardial infarction, trauma and cancer. In patients with advanced chronic kidney disease, cfDNA is connected to inflammation, and it has been associated with higher mortality. Caspase-3 plays a dominant role in apoptosis, a mechanism of programmed cell death involved in the pathogenesis and progression of chronic kidney disease (CKD). The aim of this pilot study was the evaluation of cfDNA levels and caspase-3 concentrations in patients with chronic kidney disease, in order to investigate the potential role of these molecules, deriving from inflammatory and apoptotic mechanisms, in the progression of renal damage. Methods: We compared cfDNA and caspase-3 levels in 25 CKD patients and in 10 healthy subjects, evaluating their levels based on CKD stage. We also explored correlations between cfDNA and caspase-3 levels in CKD patients and between cfDNA and caspase-3 levels and serum creatinine and urea in this population. Results: We observed that cfDNA and caspase-3 levels were higher in patients with CKD compared to healthy subjects, in particular in patients with advanced renal disease (CKD stage 5). A positive correlation between cfDNA and caspase-3 levels and between cfDNA and caspase-3 and creatinine and urea were also noticed. Conclusions: Patients with chronic kidney disease show higher levels of cfDNA and caspase-3 levels compared to the control group. Based on these preliminary results, we speculated that the worsening of renal damage and the increase in uremic toxin concentration could be associated with higher levels of cfDNA and caspase-3 levels, thus reflecting the potential role of inflammation and apoptosis in the progression of CKD. Future studies should focus on the validation of these promising preliminary results.
format Online
Article
Text
id pubmed-10488719
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104887192023-09-09 Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease Clementi, Anna Virzì, Grazia Maria Manani, Sabrina Milan de Cal, Massimo Battaglia, Giovanni Giorgio Ronco, Claudio Zanella, Monica J Clin Med Article Background: Cell-free plasma DNA (cfDNA) is circulating extracellular DNA arising from cell death mechanisms (apoptosis, necrosis, etc.). It is commonly existent in healthy individuals, but its ranks increase in diverse clinical circumstances, such as kidney disease, sepsis, myocardial infarction, trauma and cancer. In patients with advanced chronic kidney disease, cfDNA is connected to inflammation, and it has been associated with higher mortality. Caspase-3 plays a dominant role in apoptosis, a mechanism of programmed cell death involved in the pathogenesis and progression of chronic kidney disease (CKD). The aim of this pilot study was the evaluation of cfDNA levels and caspase-3 concentrations in patients with chronic kidney disease, in order to investigate the potential role of these molecules, deriving from inflammatory and apoptotic mechanisms, in the progression of renal damage. Methods: We compared cfDNA and caspase-3 levels in 25 CKD patients and in 10 healthy subjects, evaluating their levels based on CKD stage. We also explored correlations between cfDNA and caspase-3 levels in CKD patients and between cfDNA and caspase-3 levels and serum creatinine and urea in this population. Results: We observed that cfDNA and caspase-3 levels were higher in patients with CKD compared to healthy subjects, in particular in patients with advanced renal disease (CKD stage 5). A positive correlation between cfDNA and caspase-3 levels and between cfDNA and caspase-3 and creatinine and urea were also noticed. Conclusions: Patients with chronic kidney disease show higher levels of cfDNA and caspase-3 levels compared to the control group. Based on these preliminary results, we speculated that the worsening of renal damage and the increase in uremic toxin concentration could be associated with higher levels of cfDNA and caspase-3 levels, thus reflecting the potential role of inflammation and apoptosis in the progression of CKD. Future studies should focus on the validation of these promising preliminary results. MDPI 2023-08-28 /pmc/articles/PMC10488719/ /pubmed/37685683 http://dx.doi.org/10.3390/jcm12175616 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Clementi, Anna
Virzì, Grazia Maria
Manani, Sabrina Milan
de Cal, Massimo
Battaglia, Giovanni Giorgio
Ronco, Claudio
Zanella, Monica
Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title_full Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title_fullStr Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title_full_unstemmed Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title_short Plasma Cell-Free DNA and Caspase-3 Levels in Patients with Chronic Kidney Disease
title_sort plasma cell-free dna and caspase-3 levels in patients with chronic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488719/
https://www.ncbi.nlm.nih.gov/pubmed/37685683
http://dx.doi.org/10.3390/jcm12175616
work_keys_str_mv AT clementianna plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT virzigraziamaria plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT mananisabrinamilan plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT decalmassimo plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT battagliagiovannigiorgio plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT roncoclaudio plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease
AT zanellamonica plasmacellfreednaandcaspase3levelsinpatientswithchronickidneydisease